{
    "RADCURE-3507": {
        "question": "Age: 56.6, Sex: Male, ECOG PS: ECOG 0, Smoking PY: 42, Smoking Status: Current, Ds Site: Oropharynx, Subsite: Base of Tongue, T: T3, N: N2c, M : M0, Stage: IVA, Path: Squamous Cell Carcinoma, HPV: Negative, Tx Modality: ChemoRT, Chemo? : Yes, Dose: 70.0, Fx: 35, Local: none, Regional: none, Distant: Yes, 2nd Ca: none, ContrastEnhanced: 1\nAnswer: ",
        "recruit-recruiter": "1. Medical Oncologist - Your expertise is strictly limited to systemic therapy decisions, including chemotherapy and immunotherapy in head and neck cancers. - Hierarchy: Medical Oncologist",
        "initial_assessment-medical oncologist": "Step-by-step analysis as a medical oncologist:\n\n1. The provided bounding boxes are normalized coordinates within a head and neck CT scan. The first bounding box is [257, 184, 119, 257, 216, 146], and the second is [273, 137, 83, 273, 190, 112]. These coordinates likely correspond to specific anatomical or pathological regions.\n\n2. The first bounding box appears to be located in a region consistent with the oropharynx or adjacent soft tissues, possibly involving lymph nodes or tumor mass. The second bounding box is more superior and anterior, possibly involving structures such as the base of tongue or adjacent lymphatic tissue.\n\n3. From an oncologic perspective, the presence of multiple ROIs in these regions may indicate tumor involvement and/or nodal metastases, which are critical for staging and prognosis.\n\n4. Without direct visualization of the scan, but given the location and number of ROIs, this could represent a locally advanced head and neck squamous cell carcinoma with nodal involvement.\n\n5. The prognosis in such cases depends on tumor size (T stage), nodal involvement (N stage), HPV status, and treatment modality. HPV-negative tumors and extensive nodal disease generally have worse outcomes.\n\n6. The presence of multiple ROIs in these regions suggests at least N2 nodal disease, which is associated with intermediate to poor prognosis without aggressive treatment.\n\nFinal answer:\n\nAnswer: Dead",
        "initial_assessment_review_assessment-medical oncologist": "Answer: Dead",
        "Round 1-role-comment": "medical oncologist:dead",
        "Round 1-num_agents": 1,
        "Round 2-Turn 1-discuss-participate_review_assessment-medical oncologist": "Answer:no",
        "Round 2-Turn 1-ask_gap_review_assessment-medical oncologist": "---\nAnswer: no\nReason: Current expertise covers systemic therapy decisions; no gaps identified.\n---",
        "Round 2-role-comment": "medical oncologist:dead",
        "Round 2-num_agents": 1,
        "num_cooperations-panel": 0,
        "decision-Moderator": "('Answer: Alive',)"
    }
}